John McGrath, EVP & Chief Financial Officer at Atara Biotherapeutics, Inc. (ATRA), sold 4,000 shares at $15.27 ($60K) on 2017-05-16, disclosed to the SEC on 2017-05-17.
Scheduled sale ($60k) by EVP & Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.95 | 2,000 | $30K | 49.5% |
| 2 | $15.27 | 2,000 | $31K | 50.5% |
| Total | $15.11 avg | 4,000 | $60K | 100% |
| Filing → |
| ATRA | SELL | 2018-01-12 | $901K | — | Filing → |
| ATRA | SELL | 2018-01-02 | $640K | — | Filing → |
| ATRA | SELL | 2017-08-17 | $60K | — | Filing → |